Market Closed - Euronext Paris 11:35:24 2024-07-04 am EDT 5-day change 1st Jan Change
93.6 EUR +3.71% Intraday chart for bioMérieux +3.77% -6.96%

ETFs positioned on bioMérieux

Name Weight AuM 1st Jan change Investor Rating
0.97% 15 M€ -5.84%
0.26% 1,056 M€ +2.13%
0.24% 5 M€ +4.56%
0.17% 21 M€ +10.39% -
0.14% 5 M€ +10.09% -
0.14% 14 M€ +5.66% -
0.06% 6 M€ -.--% -
0.05% 3,859 M€ +18.82% -
0.05% 469 M€ -2.05%
0.05% 6 M€ -.--%
0.03% 35 M€ +6.43% -
0.03% 276 M€ +11.40% -
0.02% 10 M€ -3.35% -
0.02% 205 M€ -.--%
0.01% 284 M€ -.--%
0.01% 7 M€ +0.11% -
0.01% 786 M€ -.--%
0.01% 23 M€ -.--% -
0.01% 288 M€ +28.30%
0.01% 1,166 M€ +0.26% -
0.01% 607 M€ +0.05% -
0.01% 414 M€ +12.26% -
0.00% 36 M€ +10.84% -
0.00% 324 M€ +8.28% -
0.00% 40 M€ +7.29% -
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.6%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
93.6 EUR
Average target price
113.6 EUR
Spread / Average Target
+21.40%
Consensus